AQR Capital Management’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-237,805
| Closed | -$2.37M | – | 3528 |
|
|
2025
Q2 | $2.37M | Buy |
237,805
+11,595
| +5% | +$93.4K | ﹤0.01% | 1686 |
|
|
2025
Q1 | $1.35M | Buy |
226,210
+106,260
| +89% | +$780K | ﹤0.01% | 1837 |
|
|
2024
Q4 | $921K | Buy |
119,950
+93,699
| +357% | +$805K | ﹤0.01% | 1927 |
|
|
2024
Q3 | $268K | Sell |
26,251
-3,047
| -10% | -$46.5K | ﹤0.01% | 2444 |
|
|
2024
Q2 | $435K | Sell |
29,298
-56,870
| -66% | -$815K | ﹤0.01% | 2112 |
|
|
2024
Q1 | $1.18M | Sell |
86,168
-7,832
| -8% | -$85.3K | ﹤0.01% | 1625 |
|
|
2023
Q4 | $1.03M | Buy |
94,000
+34,620
| +58% | +$343K | ﹤0.01% | 1596 |
|
|
2023
Q3 | $650K | Buy |
59,380
+3,386
| +6% | +$43.3K | ﹤0.01% | 1762 |
|
|
2023
Q2 | $741K | Sell |
55,994
-120,828
| -68% | -$1.72M | ﹤0.01% | 1677 |
|
|
2023
Q1 | $2.41M | Sell |
176,822
-25,521
| -13% | -$457K | 0.01% | 1173 |
|
|
2022
Q4 | $3.95M | Sell |
202,343
-158,538
| -44% | -$3.1M | 0.01% | 993 |
|
|
2022
Q3 | $6.88M | Sell |
360,881
-84,229
| -19% | -$1.94M | 0.02% | 743 |
|
|
2022
Q2 | $9.17M | Buy |
445,110
+327,025
| +277% | +$7.76M | 0.02% | 685 |
|
|
2022
Q1 | $3.8M | Buy |
+118,085
| New | +$4.29M | 0.01% | 917 |
|
Other funds holding ITOS
AQR Capital Management's ITOS Position: Q3 2025 in Review
AQR Capital Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 237,805 shares — an estimated $2.37M sold.
AQR Capital Management first reported a position in ITOS in Q1 2022 and held it in 14 quarters. The position peaked at $9.17M in Q2 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- AQR Capital Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- AQR Capital Management sold 237,805 iTeos Therapeutics shares in Q3 2025, an estimated $2.37M.
- AQR Capital Management first reported a position in iTeos Therapeutics in Q1 2022 and held it in 14 quarters.
- AQR Capital Management's iTeos Therapeutics position peaked at $9.17M in Q2 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.